"studyAcronym","studyTitle","studyVersion","studyRationale","id","uuid:ID"
"H2Q-MC-LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","c8315888-8b7b-4f81-bfbf-d8c3b3a5b3ca"
